Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples